TY - JOUR
T1 - Effects of domperidone therapy on symptoms and upper gastrointestinal motility in infants with gastroesophageal reflux
AU - Grill, Bruce B.
AU - Craig Hillemeier, A.
AU - Semeraro, Lucille A.
AU - McCallum, Richard W.
AU - Gryboski, Joyce D.
N1 - Funding Information:
From the Departments of Pediatrics, Loma Linda University School of Medicine, Brown University School of Medicine, and Yale University School of Medicine. Supported in part by Grant RRO0125 from the Children's Clinical Research Center, Yale University, and by a grant from Janssen Pharmaceutical Company. Submitted for publication Jan. 26, 1984; accepted July 13, 1984. Presented in part at the Mead Johnson Research Forum for Pediatric Gastroenterotogists, Hunt Valley, Md., May 1983. Reprint requests: Bruce B. Grill, M.D., Department of Pediatrics, Loma Linda University School of Medicine, Loma Linda, CA 92350.
PY - 1985/2
Y1 - 1985/2
N2 - We evaluated the effect of domperidone, a novel prokinetic agent, on symptoms and esophageal and gastric motility in 15 infants (six boys), mean age 7.9 months, with moderate to severe gastroesophageal reflux (GER) and upper gastrointestinal motility disturbances. Patients received domperidone orally for 6 weeks and underwent weekly assessment of five GER-associated symptoms, weight change, and side effects. Mean total symptom scores significantly improved after treatment (P<0.01). Vomiting, "spitting," and coughing each improved significantly. Postprandial reflux time (defined as esophageal pH<4.0) and percent peristaltic esophageal contractions improved significantly (p<0.05). Gastric fundic contractions, present in only four infants before treatment, occurred in nine after domperidone administration. Although mean gastric emptying of isotope-labeled formula was not improved, it improved ≥10% over baseline in nine patients. Peristaltic amplitude, lower esophageal sphincter pressure, and esophageal acid clearance time were unchanged. Side effects were minimal. We conclude that domperidone is a useful and safe agent for treatment of gastroesophageal reflex in infants because it addresses the motility abnormalities inherent in the pathophysiology of the disorder.
AB - We evaluated the effect of domperidone, a novel prokinetic agent, on symptoms and esophageal and gastric motility in 15 infants (six boys), mean age 7.9 months, with moderate to severe gastroesophageal reflux (GER) and upper gastrointestinal motility disturbances. Patients received domperidone orally for 6 weeks and underwent weekly assessment of five GER-associated symptoms, weight change, and side effects. Mean total symptom scores significantly improved after treatment (P<0.01). Vomiting, "spitting," and coughing each improved significantly. Postprandial reflux time (defined as esophageal pH<4.0) and percent peristaltic esophageal contractions improved significantly (p<0.05). Gastric fundic contractions, present in only four infants before treatment, occurred in nine after domperidone administration. Although mean gastric emptying of isotope-labeled formula was not improved, it improved ≥10% over baseline in nine patients. Peristaltic amplitude, lower esophageal sphincter pressure, and esophageal acid clearance time were unchanged. Side effects were minimal. We conclude that domperidone is a useful and safe agent for treatment of gastroesophageal reflex in infants because it addresses the motility abnormalities inherent in the pathophysiology of the disorder.
UR - http://www.scopus.com/inward/record.url?scp=0021949010&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021949010&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(85)80315-2
DO - 10.1016/S0022-3476(85)80315-2
M3 - Article
C2 - 3968623
AN - SCOPUS:0021949010
SN - 0022-3476
VL - 106
SP - 311
EP - 316
JO - The Journal of Pediatrics
JF - The Journal of Pediatrics
IS - 2
ER -